Michael Gelband’s Transmedics TMDX Stock Holding History

Michael Gelband’s Portfolio TMDX Stock Details TMDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$568K	Sell	8,553 -106,792	-93%	-$9.04M	﹤0.01%	1208
2026 Q1	$11.5M	Buy	+115,345	New	+$15M	0.09%	201
2025 Q3	–	Sell	-139,407	Closed	-$18.7M	–	2020
2025 Q2	$18.7M	Buy	+139,407	New	+$15.3M	0.16%	123
2024 Q4	–	Sell	-21,405	Closed	-$3.36M	–	2058
2024 Q3	$3.36M	Sell	21,405 -41,285	-66%	-$6.36M	0.02%	554
2024 Q2	$9.44M	Buy	+62,690	New	+$7.52M	0.06%	263
2024 Q1	–	Sell	-8,401	Closed	-$663K	–	1957
2023 Q4	$663K	Buy	8,401 +3,400	+68%	+$205K	﹤0.01%	959
2023 Q3	$274K	Buy	+5,001	New	+$360K	﹤0.01%	1441

Other funds holding TMDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Michael Gelband's TMDX Position: Q2 2026 in Review

Michael Gelband reduced its Transmedics (TMDX) stake by 93% in Q2 2026, selling an estimated $9.04M and leaving 8,553 shares worth $568K. The position accounts for ﹤0.01% of the portfolio, ranked #1208.

Michael Gelband first reported a position in TMDX in Q3 2023 and has held it in 7 quarters since. The position peaked at $18.7M in Q2 2025. 371 funds tracked by Wall St. Rank hold TMDX as of Q2 2026.

Michael Gelband held 8,553 shares of Transmedics worth $568K as of Q2 2026.
Michael Gelband sold 106,792 Transmedics shares in Q2 2026, an estimated $9.04M.
Transmedics made up ﹤0.01% of Michael Gelband's portfolio in Q2 2026, its #1208 holding.
Michael Gelband first reported a position in Transmedics in Q3 2023 and has held it in 7 quarters since.
Michael Gelband's Transmedics position peaked at $18.7M in Q2 2025.
371 funds tracked by Wall St. Rank held Transmedics as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.